Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

MLA

Mueck W, et al. “Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban--an Oral, Direct Factor Xa Inhibitor--in Patients Undergoing Major Orthopaedic Surgery.” Clinical Pharmacokinetics, vol. 47, no. 3, Feb. 2008, pp. 203–16. EBSCOhost, https://doi.org/10.2165/00003088-200847030-00006.

APA

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG, Mueck, W., Eriksson, B. I., Bauer, K. A., Borris, L., Dahl, O. E., & Fisher, W. D. (2008). Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clinical Pharmacokinetics, 47(3), 203–216. https://doi.org/10.2165/00003088-200847030-00006

Chicago

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, et al. 2008. “Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban--an Oral, Direct Factor Xa Inhibitor--in Patients Undergoing Major Orthopaedic Surgery.” Clinical Pharmacokinetics 47 (3): 203–16. doi:10.2165/00003088-200847030-00006.